Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

PSD-95 is post-transcriptionally repressed during early neural development by PTBP1 and PTBP2.

Nature neuroscience | 2012

Postsynaptic density protein 95 (PSD-95) is essential for synaptic maturation and plasticity. Although its synaptic regulation has been widely studied, the control of PSD-95 cellular expression is not understood. We found that Psd-95 was controlled post-transcriptionally during neural development. Psd-95 was transcribed early in mouse embryonic brain, but most of its product transcripts were degraded. The polypyrimidine tract binding proteins PTBP1 and PTBP2 repressed Psd-95 (also known as Dlg4) exon 18 splicing, leading to premature translation termination and nonsense-mediated mRNA decay. The loss of first PTBP1 and then of PTBP2 during embryonic development allowed splicing of exon 18 and expression of PSD-95 late in neuronal maturation. Re-expression of PTBP1 or PTBP2 in differentiated neurons inhibited PSD-95 expression and impaired the development of glutamatergic synapses. Thus, expression of PSD-95 during early neural development is controlled at the RNA level by two PTB proteins whose sequential downregulation is necessary for synapse maturation.

Pubmed ID: 22246437 RIS Download

Research resources used in this publication

None found

Associated grants

  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM049662
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH060919
  • Agency: Howard Hughes Medical Institute, United States
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM049662-18
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM 49662
  • Agency: NIMH NIH HHS, United States
    Id: F32 MH84562
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM049662-19
  • Agency: NIMH NIH HHS, United States
    Id: F31 MH085462-02
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH60919
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH060919-07
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM049662-17

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Bethyl (tool)

RRID:SCR_013554

An Antibody supplier

View all literature mentions

ImageQuant (tool)

RRID:SCR_014246

Software for automatic general image analysis. It provides fully automatic analysis of 1-D gels including lane creation, background subtraction, band detection, molecular weight calibration, quantity calibration, and normalization. Editing tools are provided for cropping, rotating, and filtering images.

View all literature mentions

B6.129S2-Emx1tm1(cre)Krj/J (tool)

RRID:IMSR_JAX:005628

Mus musculus with name B6.129S2-Emx1tm1(cre)Krj/J from IMSR.

View all literature mentions

Crl:CD1(ICR) (tool)

RRID:IMSR_CRL:022

Mus musculus with name Crl:CD1(ICR) from IMSR.

View all literature mentions

Chapsyn-110/PSDF-93 (antibody)

RRID:AB_10673100

This monoclonal targets Chapsyn-110/PSDF-93

View all literature mentions

Anti-Chapsyn-110/PSD-93 Antibody (antibody)

RRID:AB_2277296

This monoclonal targets Chapsyn-110/PSD-93

View all literature mentions